Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydrazine
2. Hydrazine Dihydrochloride
3. Hydrazine Hydrate
4. Hydrazine Monohydrate
5. Hydrazine Mononitrate
6. Hydrazine Nitrate
7. Hydrazine Phosphate (1:1)
8. Hydrazine Phosphate (2:1)
9. Hydrazine Sulfate (1:1) Monosodium Salt
10. Hydrazine Sulfate (2:1)
11. Hydrazine Tartrate
12. Segidrin
1. 10034-93-2
2. Hydrazine, Sulfate
3. Hydrazine Monosulfate
4. Hydrazine Sulphate
5. Hydrazinium Sulfate
6. Hydrazonium Sulfate
7. Hydrazine Sulfate (1:1)
8. Hydrazine, Sulfate (1:1)
9. Siran Hydrazinu
10. Idrazina Solfato
11. Hydrazinium(2+) Sulfate
12. Hydrazine Hydrogen Sulfate
13. Hydrazine Sulfate Salt
14. Nsc-150014
15. Hydrazine Dihydrogen Sulfate Salt
16. Mfcd00044873
17. 1n369sat01
18. Nsc150014
19. Nsc-215190
20. Segidrin
21. Sehydrin
22. Diamidogen Sulfate
23. Hydrazinium(2+) Sulphate
24. Wln: Zz &s-o4
25. Siran Hydrazinu [czech]
26. Hydrazine Sulfate (van)
27. Idrazina Solfato [italian]
28. Hydrazinium Sulphate
29. Ccris 336
30. Hsdb 5086
31. Hydrazine; Sulfuric Acid
32. Einecs 233-110-4
33. Nsc 150014
34. Nsc 215190
35. Hydrazinsulfat
36. Idrazina Solfato [italian]
37. Unii-1n369sat01
38. Ai3-18433
39. Hydrazine Sulphate Salt
40. Dsstox_cid_703
41. Hydrazonium Sulphate
42. Hydrazine Dihydrogen Sulfate
43. Dsstox_rid_75745
44. Hydrazine Monosulphate
45. Dsstox_gsid_20703
46. Hydrazine Sulfate [mi]
47. Chembl1981828
48. Dtxsid8020703
49. Hydrazine Sulfate [hsdb]
50. Amy8941
51. Hydrazine Hydrogen Sulphate
52. Hydrazine Sulfate [mart.]
53. Hydrazine Sulfate [who-dd]
54. Hydrazine, Sulphate (1:1)
55. Tox21_302995
56. Gp-703
57. Nsc215190
58. Akos015901874
59. Hydrazinium Sulfate, Hydrazonium Sulfate
60. Ncgc00256445-01
61. Nci60_001038
62. Cas-10034-93-2
63. Db-029899
64. Hydrazine Dihydrogen Sulfate (1:1)
65. Ft-0627114
66. Hydrazine Dihydrogen Sulphate (1:1)
67. Hydrazine Sulfate Salt, Acs Reagent, >=99.0%
68. Hydrazinium Sulfate, Saj First Grade, >=97.0%
69. Hydrazinium Sulfate, Jis Special Grade, >=99.0%
70. Q413847
71. Hydrazine Sulfate Salt, P.a., Acs Reagent, 99.0%
72. Hydrazine Sulfate Salt, 99.999% Trace Metals Basis
73. Hydrazine Sulfate Salt, Vetec(tm) Reagent Grade, 97%
74. Hydrazine Sulfate Salt, Puriss. P.a., Acs Reagent, >=99.0%
| Molecular Weight | 130.13 g/mol |
|---|---|
| Molecular Formula | H6N2O4S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 0 |
| Exact Mass | 130.00482785 g/mol |
| Monoisotopic Mass | 130.00482785 g/mol |
| Topological Polar Surface Area | 135 Ų |
| Heavy Atom Count | 7 |
| Formal Charge | 0 |
| Complexity | 81.3 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antineoplastic Agents /Former use/
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
In the 1980's and early 1990's the National Cancer Institute (NCI) sponsored studies of hydrazine sulfate to evaluate whether the compound might improve patient survival or help reverse cancercachexia, a wasting syndrome that occurs in many patients who have advanced cancer. ... After hydrazine sulfate showed promising results in a small pilot study three large scale , randomized clinical trials of the compound were conducted with patients with advanced cancers. ... In two of the three clinical trials patients were permitted to take tranquilizers, alcohol, and barbiturates. ... At the request of Congress, the General Accounting Office (GAO) examined this issue beginning in July 1994 and ending in April 1995. The GAO concluded that although tranquilizers, alcohol, and barbiturates were permitted, the use of these substances did not affect the findings of these studies
DHHS;NCI Studies of Hydrazine Sulfate, Cancer Facts 9.18 (February 2001). Available from, as of July 28, 2004: https://cis.nci.nih.gov/fact/9_18.htm
Hydrazine sulfate was evaluated using 24 hour dietary recalls and body weight determinations before and after 30 days of either placebo or hydrazine (60 mg, 3 times a day) oral administration in 101 heavily pretreated cancer patients with weight loss /from cancer cachexia/. After one month, 83% of hydrazine and only 53% of placebo patients completing repeat evaluation maintained or increased their weight (P< 0.05). In addition, appetite was more frequent in the hydrazine group (63% versus 25%, P< 0.05).
PMID:3791153 Chlebowski RT et al; Cancer 59 (3): 406-10 (1987)
The growth of exptl tumors involved an intensification of acetylation of sulfadimidine. Inhibition of carcinosarcoma Walker-256 by 88% and sarcoma-180 by 36% on treatment of rats & mice with 60 mg/kg of hydrazine sulfate was followed by decreases in rate of acetylation of 39.4 & 29.4%, respectively. When treatment failed to suppress tumor growth (sarcoma-45), acetylation level showed no decrease. The results point to a correlation between growth of tumors & their inhibition on the one hand & the level of acetylation on the other.
PMID:1026855 Dilman et al; Oncology 33 (5-6): 219-21 (1976)
For more Therapeutic Uses (Complete) data for HYDRAZINE SULFATE (7 total), please visit the HSDB record page.
A 55-year-old man with squamous-cell carcinoma of the left maxillary sinus presented with a 2-week history of rash, pruritus, progressive malaise, and jaundice. The patient had previously declined to undergo surgery, radiation, and chemotherapy. To treat his cancer, the patient had instead decided to use hydrazine sulfate he obtained through an alternative medicine Internet site. ...Two weeks before his presentation, he had discontinued /4 months/ use of hydrazine sulfate, 180 mg/d ... No esophageal or gastric varices were detected. The patient never recovered from this episode despite aggressive treatment.
PMID:11103057 Hainer M et al; Annals of Internal Medicine 133(11): 877-880 (2000)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Carcinogens
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)
/Following/ a single ip administration to mice, 1 mmol/kg hydrazine sulfate was distributed rapidly to most tissues with highest levels appearing in kidney. Loss from all tissues was extensive by 24 hr. Within 1st 1 to 2 hr after administration of (15)N-hydrazine sulfate, approx 20% of dose was expired as (15)N and by 48 hr another 10-15% was eliminated.
NELSON SD, GORDON WP; ADV EXP MED BIOL 136B (BIOL REACT INTERMED-2, CHEM MECH BIOL EFF PART B) 971 (1982)
When hydrazine sulfate (1 mmole/kg) was injected ip in the rat, approx 15% was converted to nitrogen within the first 30 min, followed by a much slower conversion during 24 hr. The highest conversion was observed with iv doses, and lowest with sc doses.
DOST FN; AEROSP MED RES LAB, (TECH REP) AMRL-TR (US); ISS AMRL-TR-79-68 PROC CONF ENVIRON TOXICOL 87-100 (1979)
The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome p450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome p450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intermediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/
PMID:3271870 Erikson JM, Prough RA; J Biochem Toxicol 1 (1): 41-52 (1986)
The chemical carcinogen hydrazine is potent stimulator of guanylate cyclase. 1,1-Dimethylhydrazine and hydrazine sulfate, two chemical carcinogens, structurally related to hydrazine decrease guanylate cyclase activity in rat tissues. Hydrazine increased DNA synthesis, but 1,1-dimethylhydrazine & hydrazine sulfate decreased DNA synthesis. The relationship, if any, linking the guanylate cyclase cyclic GMP system to DNA synthesis & carcinogenesis remains to be explored.
Vesely DL et al; Enzyme 23 (5): 289-94 (1979)
API SUPPLIERS
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5444
Submission : 1983-10-07
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Digital Content
NEWS #PharmaBuzz
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
